| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | FimF41a |
| Uniprot No | P11900 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-277aa |
| 氨基酸序列 | ADWTEGQPGDIIIGGEITSPSVKWLWKTGEGLSSFSNTTNEIVKRKLNISVPTDELFLAAKMSDGIKGVFVGNTLIPKIEMASYDGSVITPSFTSNTAMDIAVKVKNSGDNTELGTLSVPLSFGAAVATIFDGDTTDSAVAHIIGGSAGTVFEGLVNPGRFTDQNIAYKWNGLSKAEMAGYVEKLMPGQSASTSYSGFHNWDDLSHSNYTSANKASYLSYGSGVSAGSTLVMNLNKDVAGRLEWVAPVTITVIYS |
| 预测分子量 | 34.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FimF41a重组蛋白的3篇代表性文献概览(注：FimF41a可能与ETEC菌毛蛋白相关，以下为模拟示例)：
---
1. **文献名称**：Cloning and expression of the F41 fimbrial subunit of enterotoxigenic Escherichia coli
**作者**：Mouricout, M.A., et al.
**摘要**：本研究成功克隆并表达了大肠杆菌F41菌毛的FimF亚基，证实其在体外能够自组装成纤维结构。实验表明重组蛋白可诱导小鼠黏膜免疫应答，为F41菌毛相关疫苗开发提供了基础。
---
2. **文献名称**：Immunogenicity of recombinant FimF protein from ETEC F41 in a murine model
**作者**：Li, Y., et al.
**摘要**：通过原核系统表达纯化的重组FimF蛋白，在小鼠模型中验证其免疫原性。结果显示，该蛋白能刺激特异性抗体产生，并对ETEC F41感染提供部分保护，提示其作为疫苗候选的潜力。
---
3. **文献名称**：Structural and functional analysis of F41 fimbriae in host adhesion
**作者**：Zhang, Q., et al.
**摘要**：解析了重组FimF蛋白的晶体结构，发现其通过特定受体结合域介导细菌与宿主肠道细胞黏附。研究为针对F41菌毛的抗菌药物设计提供了结构生物学依据。
---
**备注**：FimF41a相关研究多集中于动物致病性大肠杆菌(如ETEC)的菌毛结构与疫苗开发，实际文献需通过学术数据库(如PubMed)以“ETEC F41 fimbriae”或“FimF recombinant protein”为关键词检索确认。
FimF41a recombinant protein is derived from the F41 fimbrial adhesin of enterotoxigenic *Escherichia coli* (ETEC), a bacterial pathogen responsible for severe diarrheal diseases in humans and animals. ETEC infections are mediated by colonization factors, including fimbriae like F41. which enable bacterial adherence to host intestinal epithelial cells. The F41 fimbria is a filamentous structure composed of multiple subunits, with FimF41a being a critical component involved in receptor binding and host-pathogen interactions.
The recombinant FimF41a protein is produced through genetic engineering, where the *fimF41a* gene is cloned and expressed in heterologous systems such as *E. coli* or yeast. This approach allows scalable production of the purified protein while retaining its antigenic and functional properties. Researchers have focused on FimF41a due to its role in bacterial virulence, making it a potential target for vaccines or diagnostic tools. Studies suggest that antibodies against FimF41a can block ETEC adhesion, highlighting its relevance in immune protection.
Interest in recombinant FimF41a also stems from its application in understanding fimbrial assembly mechanisms and host-cell recognition. Structural analyses reveal conserved domains critical for binding to specific glycans on intestinal surfaces, offering insights into ETEC pathogenesis. Additionally, its recombinant form enables standardized research across laboratories, facilitating the development of subunit vaccines or therapeutics against ETEC-associated illnesses, particularly in resource-limited regions where ETEC infections remain a public health burden. Ongoing work aims to optimize expression systems and evaluate its efficacy in preclinical models.
×
